Use of Triple Quadrupole-Linear Ion Trap Mass Spectrometry as a Single LC-MS Platform in Drug Metabolism and Pharmacokinetics Studies

Mass Spectrometry in Drug Metabolism and Disposition: Basic Principles and Applications

Volumn , Issue , 2011, Pages 483-524

  Jian, Wenying ^a   Yao, Ming ^b   Wen, Bo ^c   Jones, Elliott B ^d   Zhu, Mingshe ^b  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

^d APPLIED BIOSYSTEMS   (United States)

Author keywords

High resolution mass spectrometry (HRMS) for drug metabolite detection and identification, and mass defect filtering and data mining technologies, playing key roles; Metabolite identification, using Predictive Multiple Reaction Monitoring, pMRM EPI choosing theoretical metabolite ions, for predicting product ions; Triple quadrupole linear ion trap mass spectrometry, on single LC MS platform drug metabolism and pharmacokinetics (DMPK), integral to drug discovery and development

Indexed keywords

EID: 84886468313     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470929278.ch15     Document Type: Chapter

References (71)

1. Baillie TA, Davis MR. Mass spectrometry in the analysis of glutathione conjugates. Biol Mass Spectrom 1993; 22: 319-325.
2. Bauman JN, Frederick KS, Sawant A, Walsky RL, Cox LM, Obach RS, Kalgutkar AS. Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug. Drug Metab Dispos 2008; 36: 1016-1029.
3. Bueno MJ, Aguera A,GomezMJ, HernandoMD,Garcia-Reyes JF, Fernandez-AlbaAR. Application of liquid chromatography/quadrupole-linear ion trap mass spectrometry and time-of-flight mass spectrometry to the determination of pharmaceuticals and related contaminants in wastewater. Anal Chem 2007; 79: 9372-9384.
4. Carballa M, Omil F, Lema JM, Llompart M, Garcia-Jares C, Rodriguez I, Gomez M, Ternes T. Behavior of pharmaceuticals, cosmetics and hormones in a sewage treatment plant. Water Res 2004; 38: 2918-2926.
5. Chen WG, Zhang C, Avery MJ, Fouda HG. Reactive metabolite screen for reducing candidate attrition in drug discovery. In Biological Reactive Intermediates, Vol. 6, Dansette PM, Delaforge RSM, Gilbon GG, Greim H, Jollow DJ, Monks TJ, Sipes IG. Eds. Kluwer Academic/Plenum, New York, 2001, pp.521-534.
6. Di L, Kerns EH, Li SQ, Carter GT. Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS. Int J Pharm 2007; 335: 1-11.
7. Dickinson DA, Forman HJ. Cellular glutathione and thiols metabolism. Biochem Pharmacol 2002a ; 64: 1019-1026.
8. Dickinson DA, Forman HJ. Glutathione in defense and signaling: Lessons from a small thiol. Ann NY Acad Sci 2002b ; 973: 488-504.
9. Dieckhaus CM, Fernandez-Metzler CL, King R, Krolikowski PH, Baillie TA. Negative ion tandem mass spectrometry for the detection of glutathione conjugates. Chem Res Toxicol 2005; 18: 630-638.
10. Food and Drug Administration (FDA). Guidance for Industry-Satety Testing of Drug Metabolites, FDA, Washington, DC, 2008.
11. Gan J, Harper TW, Hsueh MM, Qu Q, Humphreys WG. Dansyl glutathione as a trapping agent for the quantitative estimation and identification of reactive metabolites. Chem Res Toxicol 2005; 18: 896-903.
12. Gan J, Ruan Q, He B, Zhu M, Shyu WC, Humphreys WG. In vitro screening of 50 highly prescribed drugs for thiol adduct formation-Comparison of potential for drug-induced toxicity and extent of adduct formation. Chem Res Toxicol 2009; 22: 690-698.
13. Gao H, Materne OL, Howe DL, Brummel CL. Method for rapid metabolite profiling of drugcandidatesin freshhepatocytesusingliquidchromatographycoupledwithahybrid quadrupole linear ion trap. Rapid Commun Mass Spectrom 2007; 21: 3683-3693.
14. Gibson JD, Pumford NR, Samokyszyn VM, Hinson JA. Mechanism of acetaminopheninduced hepatotoxicity: Covalent binding versus oxidative stress. Chem Res Toxicol 1996; 9: 580-585.
15. Haroldsen PE, Reilly MH, Hughes H, Gaskell SJ, Porter CJ. Characterization of glutathione conjugates by fast atom bombardment/tandem mass spectrometry. Biomed Environ Mass Spectrom 1988; 15: 615-621.
16. Harper TW, Brassil PJ. Reaction phenotyping: Current industry efforts to identify enzymes responsible for metabolizing drug candidates. Aaps J 2008; 10: 200-207.
17. Herrin GL, McCurdy HH, Wall WH. Investigation of an LC-MS-MS (QTrap) method for the rapid screening and identification of drugs in postmortem toxicology whole blood samples. J Anal Toxicol 2005; 29: 599-606.
18. Hinson JA, Reid AB, McCullough SS, James LP. Acetaminophen-induced hepatotoxicity: Role of metabolic activation, reactive oxygen/nitrogen species, and mitochondrial permeability transition. Drug Metab Rev 2004; 36: 805-822.
19. Hopfgartner G, Varesio E, Tschappat V, Grivet C, Bourgogne E, Leuthold LA. Triple quadrupole linear ion trap mass spectrometer for the analysis of small molecules and macromolecules. J Mass Spectrom 2004; 39: 845-855.
20. Jian W, Yao M, Zhang D, Zhu M. Rapid detection and characterization of in vitro and urinary N-acetyl-L-cysteine conjugates using quadrupole-linear ion trap mass spectrometry and polarity switching. Chem Res Toxicol 2009; 22: 1246-1255.
21. Jones-Lepp TL, Stevens R. Pharmaceuticals and personal care products in biosolids/sewage sludge: The interface between analytical chemistry and regulation. Anal Bioanal Chem 2007; 387: 1173-1183.
22. Kertesz V, Van Berkel GJ, Vavrek M, Koeplinger KA, Schneider BB, Covey TR. Comparison of drug distribution images from whole-body thin tissue sections obtained using desorption electrospray ionization tandem mass spectrometry and autoradiography. Anal Chem 2008; 80: 5168-5177.
23. King R, Fernandez-Metzler C. The use of Qtrap technology in drug metabolism. Curr Drug Metab 2006; 7: 541-545.
24. King RC, Gundersdorf R, Fernandez-Metzler CL. Collection of selected reaction monitoring and full scan data on a time scale suitable for target compound quantitative analysis by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2003; 17: 2413-2422.
25. Li AC, Alton D, Bryant MS, Shou WZ. Simultaneously quantifying parent drugs and screening for metabolites in plasma pharmacokinetic samples using selected reaction monitoring information-dependent acquisition on a QTrap instrument. Rapid Commun Mass Spectrom 2005; 19: 1943-1950.
26. Li AC, Gohdes MA, Shou WZ. " N-in-one" strategy for metabolite identification using a liquid chromatography/hybrid triple quadrupole linear ion trap instrument using multiple dependent product ion scans triggered with full mass scan. Rapid Commun Mass Spectrom 2007; 21: 1421-1430.
27. Ma S, Chowdhury S. Application of liquid chromatography/mass spectrometry for metabolite identification. In Drug Metabolism in Drug Design and Development: Basic Concepts and Practice, Zhang D, Zhu M, Humphreys WG, Eds. Wiley, Hoboken, NJ, 2007; pp.319-367.
28. Ma S, Zhu M. Recent advances in applications of liquid chromatography-tandem mass spectrometry to the analysis of reactive drug metabolites. Chem Biol Interact 2009; 179: 25-37.
29. Mahajan MK, Evans CA. Dual negative precursor ion scan approach for rapid detection of glutathione conjugates using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2008; 22: 1032-1040.
30. Marquet P. Is LC-MS suitable for a comprehensive screening of drugs and poisons in clinical toxicology? Ther Drug Monit 2002a; 24: 125-133.
31. Marquet P. Progress of liquid chromatography-mass spectrometry in clinical and forensic toxicology. Ther Drug Monit 2002b ; 24: 255-276.
32. Marquet P, Saint-Marcoux F, Gamble TN, Leblanc JC. Comparison of a preliminary procedure for the general unknown screening of drugs and toxic compounds using a quadrupole-linear ion-trap mass spectrometer with a liquid chromatography-mass spectrometry reference technique. J Chromatogr B Anal Technol Biomed Life Sci 2003; 789: 9-18.
33. Maurer HH. Multi-analyte procedures for screening for and quantification of drugs in blood, plasma, or serum by liquid chromatography-single stage or tandem mass spectrometry (LC-MS or LC-MS/MS) relevant to clinical and forensic toxicology. Clin Biochem 2005; 38: 310-318.
34. Mauriala T, Chauret N, Oballa R, Nicoll-Griffith DA, Bateman KP. A strategy for identification of drugmetabolites from dried blood spots using triple-quadrupole/linear iontraphybridmass spectrometry. Rapid Commun Mass Spectrom2005; 19: 1984-1992.
35. Mori K, Hashimoto H, Takatsu H, Tsuda-Tsukimoto M, Kume T. Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development. Xenobiotica 2009; 39: 415-422.
36. Mueller CA, Weinmann W, Dresen S, Schreiber A, Gergov M. Development of a multitarget screening analysis for 301 drugs using a QTrap liquid chromatography/tandem mass spectrometry system and automated library searching. Rapid Commun Mass Spectrom 2005; 19: 1332-1338.
37. Murphy CM, Fenselau C, Gutierrez PL. Fragmentation characteristic of glutathione conjugates activated by high-energy collision. J Am Soc Mass Spectrom 1992; 3: 815-822.
38. Perloff ES, Mason AK, Dehal SS, Blanchard AP, Morgan L, Ho T, Dandeneau A, Crocker RM, Chandler CM, Boily N, Crespi CL, Stresser DM. Validation of cytochrome P450 time-dependent inhibition assays: A two-time point IC50 shift approach facilitates kinact assay design. Xenobiotica 2009; 39: 99-112.
39. Politi L, Morini L, Polettini A. A direct screening procedure for diuretics in human urine by liquid chromatography-tandem mass spectrometry with information dependent acquisition. Clin Chim Acta 2007; 386: 46-52.
40. Prakash C, Shaffer CL, Nedderman A. Analytical strategies for identifying drug metabolites. Mass Spectrom Rev 2007; 26: 340-369.
41. Raghavan N, Zhang D, Zhu M, Zeng J, Christopher L. Cyp2D6 catalyzes 5-hydroxylation of 1-(2-pyrimidinyl)-piperazine, an active metabolite of several psychoactive drugs, in human liver microsomes. Drug Metab Dispos 2005; 33: 203-208.
42. Saint-Marcoux F, Lachatre G, Marquet P. Evaluation of an improved general unknown screening procedure using liquid chromatography-electrospray-mass spectrometry by comparison with gas chromatography and high-performance liquidchromatography-Diode array detection. J Am Soc Mass Spectrom 2003; 14: 14-22.
43. Sauvage FL, Saint-Marcoux F, Duretz B, Deporte D, Lachatre G, Marquet P. Screening of drugs and toxic compounds with liquid chromatography-linear ion trap tandem mass spectrometry. Clin Chem 2006; 52: 1735-1742.
44. Scholz K, Dekant W, Volkel W, Pahler A. Rapid detection and identification of N-acetyl-L-cysteine thioethers using constant neutral loss and theoretical multiple reaction monitoring combined with enhanced product-ion scans on a linear ion trap mass spectrometer. J Am Soc Mass Spectrom 2005; 16: 1976-1984.
45. Shou WZ, Magis L, Li AC, Naidong W, Bryant MS. A novel approach to perform metabolite screening during the quantitative LC-MS/MS analyses of in vitro metabolic stability samples using a hybrid triple-quadrupole linear ion trap mass spectrometer. J Mass Spectrom 2005; 40: 1347-1356.
46. Soglia JR, Contillo LG, Kalgutkar AS, Zhao S, Hop CE, Boyd JG, Cole MJ. A semiquantitative method for the determination of reactive metabolite conjugate levels in vitro utilizing liquid chromatography-tandem mass spectrometry and novel quaternary ammonium glutathione analogues. Chem Res Toxicol 2006; 19: 480-490.
47. Soglia JR, Harriman SP, Zhao S, Barberia J, Cole MJ, Boyd JG, Contillo LG. The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro-electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent. J Pharm Biomed Anal 2004; 36: 105-116.
48. Solon EG, Balani SK, Lee FW. Whole-body autoradiography in drug discovery. Curr Drug Metab 2002; 3: 451-462.
49. Stanley SM, Wee WK, Lim BH, Foo HC. Direct-injection screening for acidic drugs in plasma and neutral drugs in equine urine by differential-gradient LC-LC coupled MS/MS. J Chromatogr B Anal Technol Biomed Life Sci 2007; 848: 292-302.
50. Takakusa H, Masumoto H, Yukinaga H, Makino C, Nakayama S, Okazaki O, Sudo K. Covalent binding and tissue distribution/retention assessment of drugs associated with idiosyncratic drug toxicity. Drug Metab Dispos 2008; 36: 1770-1779.
51. Wagner S, Scholz K, Donegan M, Burton L, Wingate J, Volkel W. Metabonomics and biomarker discovery: LC-MS metabolic profiling and constant neutral loss scanning combined with multivariate data analysis for mercapturic acid analysis. Anal Chem 2006; 78: 1296-1305.
52. Wagner S, Scholz K, Sieber M, Kellert M, Voelkel W. Tools in metabonomics: An integrated validation approach for LC-MS metabolic profiling of mercapturic acids in human urine. Anal Chem 2007; 79: 2918-2926.
53. Wang L, Zhang D, Swaminathan A, Xue Y, Cheng PT, Wu S, Mosqueda-Garcia R, Aurang C, Everett DW, Humphreys WG. Glucuronidation as a major metabolic clearance pathway of 14c-labeled muraglitazar in humans: Metabolic profiles in subjects with or without bile collection. Drug Metab Dispos 2006; 34: 427-439.
54. Wen B, Coe KJ, Rademacher P, Fitch WL, Monshouwer M, Nelson SD. Comparison of in vitro bioactivation of flutamide and its cyano analogue: Evidence for reductive activation by human NADPH: cytochrome P450 reductase. Chem Res Toxicol 2008a ; 21: 2393-2406.
55. Wen B, Fitch WL. Analytical strategies for the screening and evaluation of chemically reactive drug metabolites. Expert Opin Drug Metab Toxicol 2009a ; 5: 39-55.
56. Wen B, Fitch WL. Screening and characterization of reactive metabolites using glutathione ethyl ester in combination with Q-trap mass spectrometry. J Mass Spectrom 2009b ; 44: 90-100.
57. Wen B, Ma L, Nelson SD, Zhu M. High-throughput screening and characterization of reactive metabolites using polarity switching of hybrid triple quadrupole linear ion trap mass spectrometry. Anal Chem 2008b ; 80: 1788-1799.
58. Wen B, Ma L, Rodrigues AD, Zhu M. Detection of novel reactive metabolites of trazodone: Evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine. Drug Metab Dispos 2008c ; 36: 841-850.
59. Wen B, Ma L, Zhu M. Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact 2008d ; 173: 59-67.
60. Xia YQ, Miller JD, Bakhtiar R, Franklin RB, Liu DQ. Use of a quadrupole linear ion trap mass spectrometer in metabolite identification and bioanalysis. Rapid Commun Mass Spectrom 2003; 17: 1137-1145.
61. Yan Z, Caldwell GW. Stable-isotope trapping and high-throughput screenings of reactive metabolites using the isotope MS signature. Anal Chem 2004; 76: 6835-6847.
62. Yao M, Ma L, Duchoslav E, Zhu M. Rapid screening and characterization of drug metabolites using multiple ion monitoring-depedent MS/MS scan and postacquisition data mining on a hybrid quadrupole-linear ion trap mass spectrometer. Rapid Commun Mass Spectrom 2009; 23: 1683-1693.
63. Yao M, Ma L, Humphreys WG, Zhu M. Rapid screening and characterization of drug metabolites using a multiple ion monitoring-dependent MS/MS acquisition method on a hybrid triple quadrupole-linear ion trap mass spectrometer. J Mass Spectrom 2008; 43: 1364-1375.
64. Yao M, Zhu M, Sinz MW, Zhang H, Humphreys WG, Rodrigues AD, Dai R. Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis. J Pharm Biomed Anal 2007; 44: 211-223.
65. Zhang H, Davis CD, Sinz MW, Rodrigues AD. Cytochrome P450 reaction-phenotyping: An industrial perspective. Expert Opin Drug Metab Toxicol 2007; 3: 667-687.
66. Zhang H, Zhang D, Ray K, Zhu M. Mass defect filter technique and its applications to drug metabolite identification by high-resolution mass spectrometry. J Mass Spectrom 2009a ; 44: 999-1016.
67. Zhang Z, Zhu M, Tang W. Metabolite identification and profiling in drug design: Current practice and future directions. Curr Pharm Des 2009b ; 15: 2220-2235.
68. Zhang ZY, King BM, Wong YN. Quantitative liquid chromatography/mass spectrometry/mass spectrometry warfarin assay for in vitro cytochrome P450 studies. Anal Biochem 2001; 298: 40-49.
69. Zheng J, Ma L, Xin B, Olah T, Humphreys WG, Zhu M. Screening and identification of GSH-trapped reactive metabolites using hybrid triple quadruple linear ion trap mass spectrometry. Chem Res Toxicol 2007; 20: 757-766.
70. Zhu M, Zhang D, Zhang H, Shyu WC. Integrated strategies for assessment of metabolite exposure in humans during drug development: Analytical challenges and clinical development considerations. Biopharm Drug Dispos 2009; 30: 163-184.
71. Zhu M, Zhao W, Jimenez H, Zhang D, Yeola S, Dai R, Vachharajani N, Mitroka J. Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos 2005; 33: 500-507.